Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering. Galapagos currently trades on the Euronext under the symbol GLPG. It closed at €29.00 on Wednesday, giving the company a market cap of €895 million.
The Mechelen, Belgium-based company, which was founded in 1999 and booked €90 million in sales for the 12 months ended December 31, 2014, plans to list on the NASDAQ under the symbol GLPG. Galapagos initially filed confidentially on 2/6/2015. Morgan Stanley, Credit Suisse and Cowen & Company are the joint bookrunners on the deal.
